Securities law
Hims & Hers Health, Inc., a well-known telehealth company, has been at the center of a securities investigation due to claims of misleading statements and potential law violations. The investigation, led by DJS Law Group LLP, focuses on whether the company issued false information to investors, specifically regarding its collaboration
Class action lawsuits
Pomerantz LLP has announced that a class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) on allegations of securities fraud and other unlawful business practices. The lawsuit concerns the company's promotion and sale of compounded drugs under the guise of "personalization."
Class action lawsuits
A class action lawsuit has been filed against Hims & Hers Health, Inc. alleging violations of federal securities laws. The lawsuit seeks to recover damages on behalf of all persons and entities that purchased Hims & Hers securities between April 29, 2025, and June 23, 2025. The complaint alleges that
Class action lawsuits
The deadline for investors who purchased Novo Nordisk A/S securities between May 7, 2025, and July 28, 2025, to file a lead plaintiff motion is approaching. The class action alleges that Novo Nordisk made false and/or misleading statements about its business, operations, and prospects during this period. The
Class action lawsuits
A securities class action lawsuit has been filed on behalf of purchasers of Novo Nordisk A/S (NYSE: NVO) securities between May 7, 2025, and July 28, 2025, due to allegedly deceptive statements made by the company about its growth potential. The lawsuit claims that defendants provided false and misleading
Class action lawsuits
Levi & Korsinsky, LLP has notified investors in Novo Nordisk A/S (NYSE: NVO) of a class action securities lawsuit alleging securities fraud between May 7, 2025 and July 28, 2025. The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by the alleged false
Securities law
Investors who suffered losses in Hims & Hers Health, Inc. (HIMS) between April 29, 2025, and June 22, 2025, may be eligible to join a federal securities class action. The lawsuit alleges that the company and its executives made false and misleading statements about its business, operations, and prospects. The
Class action lawsuits
Investors in Novo Nordisk A/S ("Novo") have been notified of a class action securities lawsuit, which seeks to recover losses on behalf of investors who were allegedly affected by securities fraud between May 7, 2025 and July 28, 2025. The lawsuit claims that Novo's management
Class action lawsuits
Pomerantz LLP has announced a class action lawsuit against Hims & Hers Health, Inc. ("Hims & Hers") due to allegations of securities fraud and other unlawful business practices. The law firm is seeking to appoint a lead plaintiff for the class of investors who purchased or acquired Hims
Class action lawsuits
Hims & Hers Health, a telehealth platform company, is facing a lawsuit alleging potential securities law violations. The complaint, filed by securities law firm Bleichmar Fonti & Auld LLP, asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who
Class action lawsuits
A national plaintiffs' law firm has filed a class action lawsuit against Novo Nordisk A/S, alleging that the pharmaceutical company understated the impact of the personalization exception to the compounded GLP-1 exclusion, thereby overstating its ability to sustain long-term growth. The lawsuit claims that Novo Nordisk overstated the
Class action lawsuits
A recent announcement by Novo Nordisk terminating its collaboration with Hims & Hers due to "deceptive" marketing of Wegovy(R) has triggered securities class action lawsuits against the company. Hagens Berman, a national shareholders rights firm, is investigating the claims and urges Hims & Hers investors who suffered
